NICE recommends first drug through “managed access” model of the Cancer Drugs FundBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5398 (Published 05 October 2016) Cite this as: BMJ 2016;355:i5398
- Susan Mayor
The National Institute for Health and Care Excellence (NICE) has recommended the first drug to be provided through the new “managed access” system of the Cancer Drugs Fund. Interim guidance published in September said that osimertinib should be provided through the fund to patients with a particularly aggressive form of lung cancer for the next two years, while further data on efficacy and cost effectiveness were collected and evaluated.1
This meant that osimertinib could be used for treating locally advanced or metastatic non-small cell lung cancer expressing the epidermal growth factor receptor (EGFR) T790M …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial